Related Experiment Videos
Pleural mesothelioma
Abstract:
The difficulties in diagnosing pleural mesothelioma, both clinically and histopathologically, are documented by our experiences with this rare tumour during an 18-year-period. A rising incidence of pleural mesothelioma is reported in the literature, which is suspected to be caused by the increasing use of asbestos. This increase is not represented in a non-industrialized area. The heterogenous treatment reported in cases of malignant pleural mesothelioma illustrates the poor results achieved hitherto. Now treatment with either combination chemotherapy or radioactive drugs is recommended.
Insights
Diagnosing pleural mesothelioma is challenging, with rising incidence linked to asbestos exposure. Current treatments show poor results, but combination chemotherapy or radioactive drugs are now recommended.
Area of Science:
- Oncology
- Pathology
- Epidemiology
Background:
- Pleural mesothelioma is a rare malignancy with diagnostic challenges.
- Literature suggests increasing incidence, potentially due to asbestos use.
- This trend is not observed in non-industrialized regions.
Purpose of the Study:
- To document diagnostic difficulties and treatment outcomes for pleural mesothelioma.
- To analyze trends in a rare tumor over an 18-year period.
- To review current treatment strategies and their efficacy.
Main Methods:
- Retrospective analysis of clinical and histopathological data.
- Review of medical literature on pleural mesothelioma incidence and treatment.
- Experience-based documentation over an 18-year period.
Main Results:
- Significant clinical and histopathological diagnostic challenges were encountered.
- Incidence of pleural mesothelioma is rising, correlated with asbestos use.
- Treatment outcomes for malignant pleural mesothelioma have been poor with varied approaches.
Conclusions:
- Early and accurate diagnosis of pleural mesothelioma remains difficult.
- Asbestos exposure is a key factor in the rising incidence of this cancer.
- Improved treatment strategies, including combination chemotherapy and radioactive drugs, are recommended.